| Literature DB >> 25153708 |
Angela I Bordin1, Suresh D Pillai2, Courtney Brake1, Kaytee B Bagley1, Jessica R Bourquin1, Michelle Coleman1, Fabiano N Oliveira3, Waithaka Mwangi4, David N McMurray5, Charles C Love6, Maria Julia B Felippe7, Noah D Cohen1.
Abstract
Rhodococcus equi is an important pathogen of foals that causes severe pneumonia. To date, there is no licensed vaccine effective against R. equi pneumonia of foals. The objectives of our study were to develop an electron beam (eBeam) inactivated vaccine against R. equi and evaluate its immunogenicity. A dose of eBeam irradiation that inactivated replication of R. equi while maintaining outer cell wall integrity was identified. Enteral administration of eBeam inactivated R. equi increased interferon-γ production by peripheral blood mononuclear cells in response to stimulation with virulent R. equi and generated naso-pharyngeal R. equi-specific IgA in newborn foals. Our results indicate that eBeam irradiated R. equi administered enterally produce cell-mediated and upper respiratory mucosal immune responses, in the face of passively transferred maternal antibodies, similar to those produced in response to enteral administration of live organisms (a strategy which previously has been documented to protect foals against intrabronchial infection with virulent R. equi). No evidence of adverse effects was noted among vaccinated foals.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25153708 PMCID: PMC4143214 DOI: 10.1371/journal.pone.0105367
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Survival curves for R. equi samples in 0.9% NaCl irradiated with eBeam doses ranging from 0 to 7 kGy.
Survival curve for Concentration 1 (1×108 CFU/ml) is indicated by the symbol ○; Survival curve for Concentration 2 (1×109 CFU/ml) is indicated by the symbol ×; *0 represents true 0 and not 100 = 1.
Figure 2Ratio of IFN-γ concentration in culture media of eBeam inactivated R. equi-stimulated isolated peripheral blood mononuclear cells.
Relative quantities on day 32 relative to day 2 (log10-transformed) from 34 foals in 4 treatment groups: 1) Saline: enteral adjuvant only controls (N = 9); 2) EBRE 1: foals receiving 1×1011 R. equi eBeam irradiated with 4 kGy enterally (N = 10); 3) EBRE 2: foals receiving 2×1010 R. equi eBeam irradiated with 5 kGy enterally (N = 9); and, 4) LVRE: foals receiving 1×1010 live, virulent R. equi enterally (N = 6). Bars with differing letters indicate significant (P<0.05) differences among groups.
Figure 3Mean Ratio of R. equi-specific IgA and IgG isotypes on serum samples from foals.
OD on day 32 relative to day 2 (log10-transformed) from 34 foals in 4 treatment groups as described in Fig. 2. Bars with differing letters indicate significant (P<0.05) differences among groups. A) R. equi-specific IgA; B) R. equi-specific IgG1; C) R. equi-specific IgG4/7; D) R. equi-specific IgG3/5.
Figure 4Mean ratios of total and R. equi-specific IgA in naso-pharyngeal samples.
Relative quantities on day 32 relative to day 2 (log10-transformed) of IgA from 34 foals in 4 treatment groups as described in Fig. 2. Bars with differing letters indicate significant (P<0.05) differences among groups. A) Mean ratio (95% confidence interval) concentration total IgA; B) Mean ratio OD R. equi-specific IgA; C) Proportion of foals with increase in total IgA from day 32 relative to day 2; D) Proportion of foals with increase in R. equi-specific IgA from day 32 relative to day 2.
R. equi
-specific IgA on day 2 of life (data not shown); however, there was no significant difference among vaccine/treatment groups.